Literature DB >> 22219032

Effect of host immunity on metastatic potential in renal cell carcinoma: the assessment of optimal in vivo models to study metastatic behavior of renal cancer cells.

Minoru Kobayashi1, Tatsuo Morita, Nicole A L Chun, Aya Matsui, Masafumi Takahashi, Takashi Murakami.   

Abstract

There has been little information about metastatic behavior of renal cell carcinoma (RCC) cells because human cancers metastasize only rarely in immunodeficient mice. Moreover, it is difficult to know the effect of host immunity on RCC metastasis due to lack of such RCC cells as transplantable in not only xenograft models but also counterparts with intact immunity. Therefore, we scrutinized in vivo metastasis of RCC cells to seek for the optimal preclinical model to study metastatic behavior. The luciferase-expressing three representative human RCC cell lines (Caki-1, A498, and 786-O) and rat ACI-RCC cell which were established in our laboratory were transplanted into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice or immunocompetent ACI rats by intracardiac injection as well as orthotopic inoculation. Metastasis was monitored using a bioluminescent imaging technique. Metastasis was rare in the three human RCC cells even when they were directly disseminated into systemic circulation under the condition least susceptible to host immune attack in NOD/SCID mice. In contrast, ACI-RCC cells spontaneously metastasized to pulmonary tissue from orthotopic tumor sites and systemically spread via intracardiac route. Metastases were more extensive when the cells were inoculated into an immunodeficient host, implying suppressive effect of host immunity on colonization of RCC cells. These results suggest that the representative human RCC cells are not adequate resource to study metastasis but that the luciferase-labeled ACI-RCC cell characterized by its luminescent stability, enhanced tumorigenicity, and widespread metastatic potential provides a useful in vivo model for preclinical assessment of cancer progression and potential therapies against RCC.

Entities:  

Mesh:

Year:  2012        PMID: 22219032     DOI: 10.1007/s13277-011-0300-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  21 in total

Review 1.  Technical considerations for studying cancer metastasis in vivo.

Authors:  D R Welch
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

Review 2.  Why do cancer cells metastasize into particular organs?

Authors:  D Rusciano; M M Burger
Journal:  Bioessays       Date:  1992-03       Impact factor: 4.345

3.  PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors.

Authors:  Ker Yu; Judy Lucas; Tianmin Zhu; Arie Zask; Christine Gaydos; Lourdes Toral-Barza; Jianxin Gu; Fangbiao Li; Inder Chaudhary; Ping Cai; Jason Lotvin; Roseann Petersen; Mark Ruppen; Mahdi Fawzi; Semiramis Ayral-Kaloustian; Jerauld Skotnicki; Tarek Mansour; Philip Frost; James Gibbons
Journal:  Cancer Biol Ther       Date:  2005-05-28       Impact factor: 4.742

4.  Establishment and characterization of transplantable, luminescence labeled rat renal cell carcinoma cell lines.

Authors:  Minoru Kobayashi; Takashi Murakami; Ryosuke Uchibori; Nicole A L Chun; Eiji Kobayashi; Tatsuo Morita; Keiya Ozawa
Journal:  J Urol       Date:  2010-03-19       Impact factor: 7.450

5.  Ectopic expression of von Hippel-Lindau tumor suppressor induces apoptosis in 786-O renal cell carcinoma cells and regresses tumor growth of 786-O cells in nude mouse.

Authors:  Min Kim; Ying Yan; Kwangmoon Lee; Magda Sgagias; Kenneth H Cowan
Journal:  Biochem Biophys Res Commun       Date:  2004-07-30       Impact factor: 3.575

6.  Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice.

Authors:  S Naito; A C von Eschenbach; R Giavazzi; I J Fidler
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

7.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice.

Authors:  L D Shultz; P A Schweitzer; S W Christianson; B Gott; I B Schweitzer; B Tennent; S McKenna; L Mobraaten; T V Rajan; D L Greiner
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

8.  Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.

Authors:  Thomas D Pfister; William C Reinhold; Keli Agama; Shalu Gupta; Sonny A Khin; Robert J Kinders; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2009-07-07       Impact factor: 6.261

9.  YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway.

Authors:  S Y Wu; S L Pan; T H Chen; C H Liao; D Y Huang; J H Guh; Y L Chang; S C Kuo; F Y Lee; C M Teng
Journal:  Br J Pharmacol       Date:  2008-07-21       Impact factor: 8.739

10.  The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer.

Authors:  E J Bromwich; P A McArdle; K Canna; D C McMillan; A-M McNicol; M Brown; M Aitchison
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

View more
  3 in total

1.  Development of a realistic in vivo bone metastasis model of human renal cell carcinoma.

Authors:  Maija P Valta; Hongjuan Zhao; Alexandre Ingels; Alan E Thong; Rosalie Nolley; Matthias Saar; Donna M Peehl
Journal:  Clin Exp Metastasis       Date:  2014-04-09       Impact factor: 5.150

Review 2.  Choosing the right cell line for renal cell cancer research.

Authors:  Klaudia K Brodaczewska; Cezary Szczylik; Michal Fiedorowicz; Camillo Porta; Anna M Czarnecka
Journal:  Mol Cancer       Date:  2016-12-19       Impact factor: 27.401

3.  Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.

Authors:  V Damiano; R Rosa; L Formisano; L Nappi; T Gelardi; R Marciano; I Cozzolino; G Troncone; S Agrawal; B M Veneziani; S De Placido; R Bianco; G Tortora
Journal:  Br J Cancer       Date:  2013-04-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.